SEC Form 4 · accession 0001127602-18-014165
LABCORP HOLDINGS INC. · LH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Ratliff
Officer — CEO, Covance Drug Development
Period of report
Apr 3, 2018
Accepted (ET)
Apr 5, 2018 · 10:14 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F1,F2 | — | Apr 3, 2018 | A | 12,120 | A | — | — | Common Stock | 12,120 | 26,337 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- F2The Restricted Stock Units will vest in three installments as follows: 20% of the Restricted Stock Units will vest on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.
- F3This number reflects the aggregate number of Restricted Stock Units held by the reporting person.